AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
BigHat Biosciences Advances AI-Designed Therapeutics and Partnerships Following $75M Series C Financing.
Sep 25, 2026
Contract Type
partnership
San MateoBiotechnology
Description
BigHat Biosciences has successfully closed a $75 million Series C financing, which will help advance their AI-driven protein therapeutics platform and support collaborations with various technology and life sciences companies. The financing round was co-led by DFJ Growth and Premji Invest with significant participation from other investors.
Company Information
Company
BigHat Biosciences
Location
1900 ALAMEDA DE LAS PULGAS
San Mateo, California, United States
About
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
San MateoBiotechnology